Pfizer and Genentech Duke it Out in Court over Herceptin Biosimilar Patents Post author:Sam Post published:November 21, 2017 Post category:BioPharma Genentech is claiming that Pfizer’s proposed biosimilar infringes 40 of its patents. Source: BioSpace You Might Also Like J&J Wins FDA Nod for Erleada, the First Drug for Nonmetastatic Prostate Cancer February 14, 2018 FDA Green Lights Pfizer Drug for Rare, Fast-Killing Type of Leukemia August 17, 2017 Takeda's Partner Merges With Crestovo to Form Finch Therapeutics Group October 22, 2017